Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Appendix cancer, once rare, is now rising sharply among younger people. Firstpost brings out an expert’s views on the risk ...

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...

Jenna Scott said doctors chalked up her abdominal cramping to pregnancy symptoms or IBS. It took a year to get diagnosed with ...

Welcome to the second installment of "Cancer and the Gut Microbiome: A Miniseries". Here, we focus on how the microbiome ...

Appendix cancer is rare but it can still affect anyone The key is to stay vigilant watch out for early signs and take ...

How new diagnostic pathways can support earlier diagnosis and appropriate management in patients with lower gastrointestinal ...

BE is the only known precursor to esophageal cancer. The condition is caused by prolonged exposure of the esophagus to ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with ...

There is currently a trial at the National Institutes of Health involving a revolutionary new treatment for cancer called Tumor-Infiltrating Immunotherapy. It uses one’s own immune cells to fight ...